BDCK
Aliases: 2-bdck, 2-br-dck, 2-br-2'-oxo-pcm, 2-bromodeschloroketamine
Categories
Summary
Potency approximately 0.5-0.7× racemic ketamine by weight; larger lines are often required, increasing nasal irritation. Subjectively described as warm, euphoric, and floaty with weaker dissociation than ketamine and a noticeably shorter plateau. Limited human data; virtually all knowledge comes from small animal studies and user reports. Exercise conservative dosing, weigh milligram-accurately, allow 2 hours between redoses to reduce cumulative toxicity. BDCK was used as an NMDA-antagonist control compound in antidepressant research.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Insufflated | - | - | - | 220+(↑nasaldamagerisk)+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects |
|---|---|---|---|---|---|
| Insufflated | 5-15 min | 10-20 min | 30-60 min | 45-90 min | 1-3 hrs |
| Intramuscular | 2-5 min | 5-15 min | 30-60 min | 45-90 min | 1-3 hrs |
Tolerance
Build-up
develops over 1–4 weeks of regular use
Reset
days to weeks depending on duration of use
Effects
Positive
- Pain relief
- Stimulation
- Physical euphoria
- Analgesia
Negative
- Motor impairment
- Numbness
- Loss of balance
- Nausea
- Physical disconnection
- Sedation
Positive
- Euphoria
- Conceptual thinking
- Afterglow
Negative
- Cognitive disconnection
- Motor control loss
- Thought deceleration
- Memory suppression
- Analysis suppression
- Emotion suppression
- Dizziness
- Physical autonomy
- Time distortion
Positive
- Bodily lightness
- Increased music appreciation
Negative
- Spatial disorientation
- Double vision
- Disinhibition
- Tactile suppression
- Closed-eye visuals
- Vibrating vision
- Visual disconnection
- Auditory distortion